Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur nisl arcu, gravida at ante eget, ornare congue diam. Suspendisse tempus tortor massa. Maecenas dignissim mattis posuere. Nam ac tristique nibh. Vestibulum at diam vitae nunc ullamcorper ultrices. Pellentesque tristique tortor quis justo sollicitudin, eu venenatis leo faucibus. Nam tortor lacus, semper at auctor at, bibendum vel enim. Morbi fringilla, massa sed sagittis ultrices, elit ipsum blandit diam, maximus ultricies dui enim et justo. Integer lacinia massa eu magna fringilla, ac convallis nibh sagittis. Maecenas venenatis felis eget tellus placerat dictum.
More from Pink Sheet Perspectives
- • By
The European Medicines Agency is preparing to roll out simplified transparency rules for its Clinical Trials Information System in mid-2024. This article looks at what will change and the impact on the thousands of trials that are already in the system.
- • By
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
- • By
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.








